Cargando…
The use of antenatal magnesium sulfate for neuroprotection for infants born prematurely
Cerebral palsy occurs in three to four infants per 1000 live births. Preterm birth prior to 34 weeks’ gestation is a major risk factor. Five randomized controlled trials of antenatal magnesium sulfate (MgSO(4)) found a trend of reduced risk of cerebral palsy and mortality in preterm infants. Three m...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Faculty of 1000 Ltd
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998849/ https://www.ncbi.nlm.nih.gov/pubmed/21170373 http://dx.doi.org/10.3410/M2-78 |